Phase 1Active, not recruiting
A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors
A Phase 1 Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of GEN1042 Monotherapy and in Combination With Pembrolizumab ± Chemotherapy in Japanese Subjects With Malignant Solid Tumors
- Sponsor
- Genmab (Industry)
- Enrolment
- 8 enrolled
- Conditions
- Malignant Solid Tumor
- Interventions
- GEN1042; Pembrolizumab; Cisplatin; Carboplatin; 5-Fluorouracil
- Ages
- adults, older adults
- Registry
- NCT06057038, jRCT2031230438
Full record on ClinicalTrials.gov
From the registry
This study evaluating GEN1042 will include multiple parts. In this study, GEN1042 alone (phase 1a) or GEN1042 in combination with other anticancer drug(s) (phase 1b) will be evaluated in Japanese participants. The main purpose is to assess the safety and tolerability of GEN1042 monotherapy or GEN1042 in combination in Japanese study participants with cancer.
Primary outcomes
- Number of Participants with Dose Limiting Toxicities (DLTs)
- Percentage of Participants with Adverse Events (AEs)
History
Primary completion expected
Last registry update
Started
Registered